liraglutide
DrugOther names: Victoza
NCT Number: NCT02351232
A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes patients in suboptimal glycemic control.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2 / Phase 3
Steno Diabetes Center, Gentofte Municipality, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Victoza
Time frame: 6 months
Change in HbA1c from baseline to end of study (time 6 months)
Time frame: 6 months
Change in weight from baseline to end of study (time 6 months)
Time frame: 6 months
Change in insulin pump settings from baseline to 3 weeks, 3 months and 6 months
Time frame: 6 months
Change in glucose variability from baseline to 3 weeks, 3 months and 6 months
Time frame: 6 months
Change in body composition from baseline to 6 months
Time frame: 6 months
Change in blood pressure from baseline to 6 months
Time frame: 6 months
Change in lipid profile from baseline to 6 months
Time frame: 6 months
Frequency of hypoglycemia during the 6-month study period
Time frame: 6 months
Change in kidney function from baseline to 6 months
Time frame: 6 months
Number of daily blood glucose measurements during the 6-month study period
Time frame: 6 months
Change in dietary behavior from baseline to 3 and 6 months
Time frame: 6 months
Change in treatment satisfaction from baseline to 3 and 6 months
Time frame: 6 months
Change in anxiety and depression from baseline to 6 months
Hvidovre University Hospital
Other
The Lira Pump Trial. The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized Placebo-Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05488119
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT07696780
Autoimmune Diseases, Diabetes Mellitus
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT05610111
Autoimmune Diseases, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial DetailsNCT06308549
Autoimmune Diseases, Diabetes Distress
Bad Mergentheim, Baden-Wurttemberg, Germany
View Trial Details